Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexate

Abstract

Purpose

Hyperhydration and urinary alkalinization is implemented with all high-dose (HD)-methotrexate infusions to promote excretion and prevent precipitation of methotrexate in the renal tubules. Our institution utilized enteral alkalinizing agents (sodium bicarbonate tablets and sodium citrate/citric acid solution) to alkalinize the urine of patients receiving HD-methotrexate during a parenteral sodium bicarbonate and sodium acetate shortage. The purpose of this study is to establish the safety and efficacy of the enteral route for urine alkalinization.

Methods

A single-center, retrospective, cohort study was conducted comparing cycles of HD-methotrexate using enteral alkalinizing agents to parenteral sodium bicarbonate. The primary objective was to compare the time, in hours, from administration of first inpatient administered dose of alkalinizing agent to time of achieving goal urine pH. Secondary objectives evaluated total dose of sodium bicarbonate required to achieve goal urine pH, time from start of urine alkalinizing agent until time of achieving methotrexate level safe for discharge, and toxicities associated with methotrexate and the alkalinizing agents.

Results

A total of 118 patients were included in this study, equally divided into two cohorts based on parenteral versus enteral routes of administration. No statistical difference was determined between the two cohorts regarding time to goal urine pH (6.5 h versus 7.9 h, P = 0.051) or regarding time to methotrexate level deemed safe for discharge (63.5 h versus 62.5 h, p = 0.835). There were no significant differences in methotrexate-induced toxicities.

Conclusion

Our study found enteral routes of urine alkalinization to be a viable alternative to the traditional parenteral sodium bicarbonate, especially during parenteral sodium bicarbonate and acetate shortages.

Keywords

Sodium bicarbonate urine alkalinization methotrexate

Get full access to this article

View all access options for this article.

References

Walling

. From methotrexate to premetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24: 37–77.

Widemann

Adamson

. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694–703.

Green

Chamberlain

. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009; 63: 599–604.

Kintzel

Campbell

Yost

. Reduced time for urinary alkalinization before high-dose methotorexate with preadmission oral bicarbonate. J Oncol Pharm Practice 2011; 18: 239–244.

Von hoff

Penta

Helman

. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977; 61: 745–748.

Treon

Chabner

. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322–1329.

Sand

Jacobsen

. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981; 19: 453–456.

Stoller

Hande

Jacobs

. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 1977; 297: 630–634.

Pitman

Frei

. Weekly methotrexate-calcium leucovorin rescue: Effect of alkalinnization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-hodgkin's lymphoma. Cancer Treat Rep 1977; 61: 695–701.

10.

Chan

Evans

Pratt

. Recovery from toxicity associated with high-dose methotrexate: Prognostic factors. Cancer Treat Rep 1977; 61: 797–804.

11.

Rider

Templet

Daley

. Clinical dilemmas and review of strategies to manage drug shortages. J Pharm Pract 2013; 26: 183–191.

12.

Cancer Therapy Evaluation Program, National Cancer Institute. Common terminology criteria for adverse events v.4.0 (CTCAE), http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed June 2014).